Comparative Pharmacology
Head-to-head clinical analysis: ATACAND HCT versus MICROZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATACAND HCT versus MICROZIDE.
ATACAND HCT vs MICROZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ATACAND HCT is a combination of candesartan, an angiotensin II receptor blocker (ARB), and hydrochlorothiazide, a thiazide diuretic. Candesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively antagonizing the AT1 receptor, leading to vasodilation and reduced blood pressure. Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule of the nephron, increasing sodium, chloride, and water excretion, thereby reducing plasma volume and blood pressure.
Inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule of the nephron, reducing reabsorption of sodium and chloride, leading to increased excretion of water and electrolytes, and a decrease in blood volume and peripheral vascular resistance.
One tablet orally once daily. Initial dose: 16 mg candesartan/12.5 mg hydrochlorothiazide. Titrate to maximum 32 mg candesartan/25 mg hydrochlorothiazide once daily.
12.5-25 mg orally once daily for hypertension; 25-100 mg orally once daily for edema.
None Documented
None Documented
Candesartan: ~9 hours (terminal). Hydrochlorothiazide: 6-15 hours (terminal, mean ~10 hours).
Terminal elimination half-life: 8-12 hours (prolonged in renal impairment; up to 30 hours in severe insufficiency).
Candesartan: ~33% renal, ~67% biliary/fecal. Hydrochlorothiazide: >95% renal.
Primarily renal (approximately 70% unchanged drug; remainder as metabolites and conjugates); minimal biliary/fecal (<10%).
Category C
Category C
Angiotensin II Receptor Blocker / Thiazide Diuretic
Thiazide Diuretic